NCT02087865

Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 89 (actual)
• Sponsor: The Cleveland Clinic · Academic / Other
• Sex: All
• Age: 60 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This study examines the sensitivity of functional MRI to detect brain changes caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk for Alzheimer's Disease.

Detailed description

This 24-week study will examine the sensitivity of functional MRI to detect brain changes caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk for Alzheimer's Disease. Participants with a family history of Alzheimer's Disease will be eligible for this study. Participants without a family history of AD will also be enrolled to serve as a control group.

Conditions

• Genetic Risk for Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	donepezil HCL
DRUG	Placebo

Timeline

• Start date: 2014-05-01
• Primary completion: 2021-12-20
• Completion: 2021-12-20
• First posted: 2014-03-14
• Last updated: 2023-08-30
• Results posted: 2023-08-30

Locations

1 site across 1 country: United States